Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.28 - $2.45
Previous CloseN/A
Volume2.02M
Average Volume (3M)23.54M
Market Cap
$230.45M
Enterprise Value$135.08M
Total Cash (Recent Filing)$260.13M
Total Debt (Recent Filing)$64.80M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
May 01, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding361,492,300
10 Day Avg. Volume8,371,449
30 Day Avg. Volume23,537,068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.22
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.43
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$5.00Price Target Upside646.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PositionLexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory, and sales milestone payments.
Product DevelopmentThe preclinical oral obesity asset LX9851 is considered the most interesting in the pipeline.
Strategic PartnershipsLexicon's exclusive licensing agreement with Novo Nordisk for its obesity asset LX9851 is a key positive development that substantially validates LXRX's obesity platform and provides much-needed capital flexibility.
Bears Say
Clinical RisksThere are remaining execution risks across LXRX's clinical pipeline and anticipated cash burn.
Financial ConcernsThe cash balance of $238M is modeled to be sufficient only into the second half of 2026.
Revenue PerformanceFollowing the elimination of all promotional efforts, U.S. net product revenue for INPEFA remained flat compared to the previous quarter.
---
Ownership Overview
50.83% Insiders
11.90% Mutual Funds
0.26% Other Institutional Investors
32.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.28 and its highest was $2.45 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $230.45M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 7 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Mar 06, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.127 by $0.037.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.1.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.127. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
---
Lexicon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (646.27% Upside)
$5.00 (646.27% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.74%
12-Months-Change
Fundamentals
Return on Equity
-167.66%
Trailing 12-Months
Asset Growth
30.07%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
---
LXRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook. While there were significant achievements in clinical trials, licensing agreements, and financial position improvements, these were balanced by increased net losses, operating expenses, and market challenges in the US heart failure sector.Read More>---
LXRX Stock 12 Month Forecast
Average Price Target
$5.00
▲(646.27% Upside)
Technical Analysis
Protalix
―
DBV Technologies SA - American
―
Gossamer Bio
―
Foghorn Therapeutics
―
Terns Pharmaceuticals
―
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-17.95%
reiterated a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -17.95% per trade.
---